Clinical efficacy and safety: cardiovascular system
The European Medicines Agency's scientific guidelines on the clinical evaluation of human medicines used in conditions affecting the cardiovascular system help medicine developers prepare marketing authorisation applications.
For a complete list of scientific guidelines currently open for consultation, see Public consultations.
- Clinical investigation on medicinal products in the treatment of hypertension - Scientific guideline
- ICH E12 Principles for clinical evaluation of new antihypertensive drugs - Scientific guideline
- Paediatric addendum to the guideline on clinical investigation on medicinal products in the treatment of hypertension - Scientific guideline
- Addendum to the note for guidance on antiarrhythmics on atrial fibrillation and atrial flutter - Scientific guideline
- Antiarrhythmics - Scientific guideline
- Clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation - Scientific guideline
- ICH E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs - Scientific guideline
- ICH E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs - Scientific guideline
- Need for a paediatric addendum of the guideline on clinical investigation of medicinal products for the treatment and prophylaxis of venous thromboembolic disease - Scientific guideline
- Clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in non-surgical patients - Scientific guideline
- Clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery - Scientific guideline
- Clinical investigation of medicinal products for the treatment of venous thromboembolic disease - Scientific guideline
- Clinical investigation of medicinal products for the treatment of acute heart failure - Scientific guideline
- Paediatric addendum on the CHMP guideline on clinical investigation of medicinal products for the treatment of acute heart failure - Scientific guideline
- Clinical investigation of medicinal products in the treatment of chronic heart failure - Scientific guideline
- Clinical and non-clinical evaluation during the consultation procedure on medicinal substances contained in drug-eluting (medicinal-substance-eluting) coronary stents - Scientific guideline
- Clinical investigation of anti-anginal medicinal products in stable angina pectoris - Scientific guideline
- Clinical development of fibrinolytic medicinal products in the treatment of patients with ST -segment elevation acute myocardial infarction (STEMI) - Scientific guideline
- Clinical investigation of new medicinal products for the treatment of acute coronary syndrome - Scientific guideline
- Clinical investigation of medicinal products in the treatment of peripheral-arterial occlusive disease - Scientific guideline
- Evaluation of medicinal products for cardiovascular disease prevention - Scientific guideline
- Assessment of cardiovascular safety profile of medicinal products - Scientific guideline
- Assessment of cardiovascular safety profile of medicinal products - Scientific guideline
- Gender differences in cardiovascular diseases - Scientific guideline
Position statements